Dual RAAS Blockade in CKD: Does the Hype have Teeth?

Kidney360. 2022 Apr 19;3(7):1277-1280. doi: 10.34067/KID.0000912022. eCollection 2022 Jul 28.

Authors

Jonathan S Chávez-Íñiguez^{1

2}, Brian S Rifkin³

Affiliations

¹ Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde.
² University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico.
³ Division of Nephrology, Hattiesburg Clinic, Hattiesburg, Mississippi.

No abstract available

Keywords: ACE ihibitor; ARB; CKD; MRA; RAAS; aldosterone; angiotensin II; clinical nephrology; dual blockade.

MeSH terms

Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Humans
Renal Insufficiency, Chronic* / drug therapy
Renin-Angiotensin System*

Substances

Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors